You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 9,034,391

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,034,391

Title:	Compositions with enhanced bioavailability and fast acting inhibitor or gastric acid secretion
Abstract:	The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion. The present invention also relates to the use of one or more water soluble zinc salts, administered in combination with a therapeutic compound or agent (second therapeutic agent) which may be delivered orally with enhanced bioavailability (compared to compounds which are administered in the absence of water soluble zinc salts) or other favorable benefits. In addition, therapeutic agents which exhibit sensitivity to low pH may be advantageously orally administered in combination with an effective amount of at least one water soluble zinc salt. Compositions according to the present invention exhibit greater bioavailability of the active agent when formulated in combination with a water soluble zinc salt in oral dosage form than when administered with the water soluble zinc salt.
Inventor(s):	Geibel; John P. (Branford, CT), Kirchhoff; Philipp (Attendorn, DE)
Assignee:	YALE UNIVERSITY (New Haven, CT)
Application Number:	12/452,637
Patent Claims:	1. A pharmaceutical composition in oral dosage form for oral administration to a human patient in need consisting essentially of effective amounts of at least one pharmaceutically acceptable water soluble zinc salt in an amount which rapidly elevates the pH of gastric juices of a patient after oral administration to a pH of at least about 3.0 within no more than about one hour after said composition is orally administered to said patient in combination with an anticancer effective amount of at least one chemotherapeutic agent in said composition which is degraded by acid in the stomach of said patient such that said therapeutic agent(s) exhibits greater bioavailability when administered in combination with said water soluble zinc salt than in the absence of said water soluble zinc salt due to the increase in the pH of the gastric juices effected by said zinc salt, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient, wherein said water soluble zinc salt is selected from the group consisting of zinc chloride, zinc gluconate, zinc acetate or a mixture thereof. 2. The composition according to claim 1 wherein said water soluble zinc salt is zinc acetate. 3. The composition according to claim 1 wherein said mixture of water soluble zinc salts comprises two water soluble zinc salts. 4. The composition according to claim 1 wherein said zinc salt is zinc chloride. 5. The composition according to claim 3 wherein said water soluble zinc salt is zinc gluconate. 6. The composition according to claim 3 wherein said two water soluble zinc salts are zinc chloride and zinc gluconate. 7. The composition according to claim 1 wherein said chemotherapeutic agent is selected from the group consisting of 13-cis-Retinoic Acid; 2-Chlorodeoxyadenosine; 5-Azacitidine; 5-Fluorouracil; 6-Mercaptopurine; 6-Thioguanine; Abraxane; Isotretinoin; Actinomycin-D; Doxorubicin Hydrochloride; Anagrelide; Hydrocortisone; Aldesleukin; Alemtuzumab; Pemetrexed; Alitretinoin; Vinblastine; Melphalan; All-transretinoic Acid; Alphahlterferon; Altretamine; Amethopterin; Amifostine; Aminoglutethimide; Aminoglutethimide; Anagrelide; Asparaginase; Hydrocortone Phosphate; Leurocristine; Lenalidomide; Letrozole; Leucovorin; Leukeran; Sargramostim; Leuprolide; Cladribin; Liposomal Ara-C; Deltasone; Lomustine; L-phenylalanine mustard; L-Sarcolysin; Leuprolide Acetate; Procarbazine; Maxidex; Mechlorethamine; Mechlorethamine Hydrochloride; Methylprednisolone; Megestrol Acetate; Melphalan; Mercaptopurine; Mesna; Methotrexate; Nilutamide; Anastrozole; Arabinosylcytosine; Darbepoetin Alpha; Pamidronate; Exemestane; Nelarabine; Arsenic Trioxide; Atragen; Bevacizumab; Azacitidine; BCG (Bacillus Calmette Guerin); BCNU (Carmustine); Bexarotene; Tositumomab; Bicalutamide; Bleomycin; Bortezomib; Busulfan; Eribitux; Calcium Leucovorin; Alemtuzumab; Irinotecan hydrochloride; Camptothecin-11; Capecitabine; Carboplatin; Bicalutamide; CC-5013 (Revlimid); CCNU (lomustine); CDDP (Cisplatin); CeeNU; Daunorubicin; Cetuximab; Chlorambucil; Mitomycin; Mitomycin-C; Mitoxantrone; Mustine; Mitomycin; Hydroxyurea; Gemtuzumab Ozogamicin; Vinorelbine Tartrate; Nelarabine; Cyclophosphamide; Pegfilgrastim; Oprelvekin; Filgrastim; Sorafenib; Nilutamide; Pentostatin; Nitrogen Mustard; Genox; Mitoxantrone; Octreotide; Octreotide acetate; Pegylated asparaginase; Denileukin Diftitox; Paclitaxel; Oprevelkin; Prednisolone Sodium Phosphate; Prednisone; Oxaliplatin; Paclitaxel Protein-bound; Pamidronate; Panitumumab; Paraplatin; Dactinomycin; Topotecan; Cyclophosphamide; Aminoglutethimide; Cytarabine; Cytarabine Liposomal; Dacarbazine; Dacogen; Dactinomycin; Dasatinib; Daunomycin; Daunorubicin Hydrochloride; Daunorubicin Liposomal; Decadron; Decitabine; Prednisolone; Prednisone; Denileukin diftitox; Dexamethasone; Dexamethasone acetate; Dexamethasone Sodium Phosphate; Dexasone; Dexrazoxane; Novantrone; Diodex; Docetaxel; Doxorubicin; Hydroxyurea; Dacarbazine; PEG Interferon; Pegaspargase; Pegfilgrastim; Peginterferon alfa-2b; PEG-L-asparaginase; PEMETREXED; Pentostatin; Phenylalanine Mustard; Procarbazine; Epoetin Alfa; Aldesleukin; Prolifeprospan 20 with Carmustine; Mercaptopurine; Raloxifene; Trexall; Rituximab; Rubidomycin hydrochloride; Octreotide Acetate; Hydrocortisone Sodium Succinate; Methylprednisolone sodium succinate; Sorafenib; Dasatinib; Gleevec; Streptozocin; SU11248; Sunitinib; Sunitinib Malate; Tamoxifen; Erlotinib; Bexarotene; Epirubicin hydrochloride; Oxaliplatin; Estramustine; Epirubicin; Epoetin alfa; Cetuximab; Erlotinib; Erwinia L-asparaginase; Ethyol; Etoposide Phosphate; Etoposide; Flutamide; Raloxifene; Exemestane; Toremifene; Fulvestrant; Letrozole; Filgrastim; Floxuridine; Fludarabine; Fluoxymesterone; Flutamide; Floxuridine; Fulvestrant; Neupogen; Gefitinib; Gemcitabine; Gemtuzumab; ozogamicin; Carmustine Wafer; Goserelin; Granulocyte Colony Stimulating Factor; Docetaxel; Temozolonaide; Teniposide; Thiotepa; Thalidomide; BCG (TheraCys strain); Thioguanine; Thiophosphamide; Thiotepa; Etoposide; Topotecan; Toremifene; Tositumomab; Trastuzumab; Tretinoin; Arsenic; VCR; Panitumumab; Vinblastine Sulfate Bortezomib; Azacitidine; Vinblastine; Vinblastine Sulfate; Vincristine; Vinorelbine; Vinorelbine tartrate; VM-26; Vorinostat; Teniposide; Capecitabine); Streptozocin; Fluoxymesterone; Trastuzumab; Hexadrol; Altretamin; Hexamethylmelamine; Hycamtin; Hydroxyurea; Ibritumomab; Ibritumornab Tiuxetan; Idarubicin; Ifosfamide; IFN-alpha; IL-11; IL-2; Imatinib mesylate; Imidazole Carboxamide; Interferon alfa; Interferon Alfa-2b (PEG Conjugate); Interleukin-2; interleukin-11; interferon alfa-2b; Getfitinib; Irinotecan; Isotretinoin; Dexrazoxane; Goserelin; Zoledronic acid; Zolinza and mixtures thereof. 8. The composition according to claim 1 wherein said therapeutic agent is a mixture of chemotherapeutic agent(s). 9. A method of increasing the bioavailability and/or reducing or alleviating the side effects of at least one orally administered chemotherapeutic agent in the treatment of cancer in a human patient which is unstable to low pH in the stomach of said patient after oral administration comprising administering a composition consisting essentially of an anticancer effective amount of said agent(s) in combination with an effective amount of at least one pharmaceutically acceptable water soluble zinc salt which rapidly raises the pH of gastric juice in the stomach of said patient to at least about 3.0 after no longer than about one hour after oral administration to said patient such that said chemotherapeutic agent(s) exhibits greater bioavailability and/or reduced side effects when administered in combination with said water soluble zinc salt than in the absence of said water soluble zinc salt due to the increase in the pH of the gastric juices effected by said water soluble zinc salt, wherein said water soluble zinc salt is selected from the group consisting of zinc chloride, zinc gluconate, zinc acetate or a mixture thereof. 10. The method according to claim 9 wherein said water soluble zinc salt is zinc acetate. 11. The method according to claim 9 wherein said mixture of water soluble zinc salts comprises two water soluble zinc salts. 12. The method according to claim 9 wherein said water soluble zinc salt is zinc chloride. 13. The method according to claim 9 wherein said water soluble zinc salt is zinc gluconate. 14. The method according to claim 11 wherein said two water soluble zinc salts are zinc chloride and zinc gluconate. 15. The method according to any of claims 9-14 wherein said chemotherapeutic agent(s) is selected from the group consisting of selected from the group consisting of 13-cis-Retinoic Acid; 2-Chlorodeoxyadenosine; 5-Azacitidine; 5-Fluorouracil; 6-Mercaptopurine; 6-Thioguanine; Abraxane; Isotretinoin; Actinomycin-D; Doxorubicin Hydrochloride; Anagrelide; Hydrocortisone; Aldesleukin; Alemtuzumab; Pemetrexed; Alitretinoin; Vinblastine; Melphalan; All-transretinoic Acid; Alphahlterferon; Altretamine; Amethopterin; Amifostine; Aminoglutethimide; Aminoglutethimide; Anagrelide; Asparaginase; Hydrocortone Phosphate; Leurocristine; Lenalidomide; Letrozole; Leucovorin; Leukeran; Sargramostim; Leuprolide; Cladribin; Liposomal Ara-C; Deltasone; Lomustine; L-phenylalanine mustard; L-Sarcolysin; Leuprolide Acetate; Procarbazine; Maxidex; Mechlorethamine; Mechlorethamine Hydrochloride; Methylprednisolone; Megestrol Acetate; Melphalan; Mercaptopurine; Mesna; Methotrexate; Nilutamide; Anastrozole; Arabinosylcytosine; Darbepoetin Alpha; Pamidronate; Exemestane); Nelarabine; Arsenic Trioxide; Atragen; Bevacizumab; Azacitidine; BCG (Bacillus Calmette Guerin); BCNU (Carmustine); Bexarotene; Tositumomab; Bicalutamide; Bleomycin; Bortezomib; Busulfan; Eribitux; Calcium Leucovorin; Alemtuzumab; Irinotecan hydrochloride; Camptothecin-11; Capecitabine; Carboplatin; Bicalutamide; CC-5013 (Revlimid); CCNU (lomustine); CDDP (Cisplatin); CeeNU; Daunorubicin; Cetuximab; Chlorambucil; Mitomycin; Mitomycin-C; Mitoxantrone; Mustine; Mitomycin; Hydroxyurea; Gemtuzumab Ozogamicin; Vinorelbine Tartrate; Nelarabine; Cyclophosphamide; Pegfilgrastim; Oprelvekin; Filgrastim; Sorafenib; Nilutamide); Pentostatin; Nitrogen Mustard; Genox; Mitoxantrone; Octreotide; Octreotide acetate; Pegylated asparaginase; Denileukin Diftitox; Paclitaxel; Oprevelkin; Prednisolone Sodium Phosphate; Prednisone; Oxaliplatin; Paclitaxel Protein-bound; Pamidronate; Panitumumab; Paraplatin; Dactinomycin; Topotecan; Cyclophosphamide; Aminoglutethimide; Cytarabine; Cytarabine Liposomal; Dacarbazine; Dacogen; Dactinomycin; Dasatinib; Daunomycin; Daunorubicin Hydrochloride; Daunorubicin Liposomal; Decadron; Decitabine; Prednisolone; Prednisone; Denileukin diftitox; Dexamethasone; Dexamethasone acetate; Dexamethasone Sodium Phosphate; Dexasone; Dexrazoxane; Novantrone; Diodex; Docetaxel; Doxorubicin; Hydroxyurea; Dacarbazine; PEG Interferon; Pegaspargase; Pegfilgrastim; Peginterferon alfa-2b; PEG-L-asparaginase; PEMETREXED; Pentostatin; Phenylalanine Mustard; Procarbazine; Epoetin Alfa; Aldesleukin; Prolifeprospan 20 with Carmustine; Mercaptopurine; Raloxifene; Trexall; Rituximab; adriamycin; Rubidomycin hydrochloride; Octreotide Acetate; Hydrocortisone Sodium Succinate; Methylprednisolone sodium succinate; Sorafenib; Dasatinib; Gleevec; Streptozocin; SU11248; Sunitinib; Sunitinib Malate; Tamoxifen; Erlotinib; Bexarotene; Epirubicin hydrochloride; Oxaliplatin; Estramustine; Epirubicin; Epoetin alfa; Cetuximab; Erlotinib; Erwinia L-asparaginase; Ethyol; Etoposide Phosphate; Etoposide; Flutamide; Raloxifene; Exemestane; Toremifene; Fulvestrant; Letrozole; Filgrastim; Floxuridine; Fludarabine; Fluoxymesterone; Flutamide; Floxuridine; Fulvestrant; Neupogen; Gefitinib; Gemcitabine; Gemtuzumab; ozogamicin; Carmustine Wafer; Goserelin; Granulocyte Colony Stimulating Factor; Docetaxel; Temozolomide; Teniposide; Thiotepa; Thalidomide; BCG (TheraCys strain); Thioguanine; Thiophosphamide; Thiotepa; Etoposide; Topotecan; Toremifene; Tositumomab; Trastuzumab; Tretinoin; Arsenic; VCR; Panitumumab; Vinblastine Sulfate Bortezomib; Azacitidine; Vinblastine; Vinblastine Sulfate; Vincristine; Vinorelbine; Vinorelbine tartrate; VM-26; Vorinostat; Teniposide; Capecitabine); Streptozocin; Fluoxymesterone; Trastuzumab; Hexadrol; Altretamin; Hexamethylmelamine; Hycamtin; Hydroxyurea; Ibritumomab; Ibritumomab Tiuxetan; Idarubicin; Ifosfamide; MN-alpha; IL-11; IL-2; Imatinib mesylate; Imidazole Carboxamide; Interferon alfa; Interferon Alfa-2b (PEG Conjugate); Interleukin-2; Interleukin-11; interferon alfa-2b; Getfitinib; Irinotecan; Isotretinoin; Dexrazoxane; Goserelin; Zoledronic acid; Zolinza and mixtures thereof. 16. The method according to claim 9 wherein said chemotherapeutic agent(s) is a mixture of chemotherapeutic agents. 17. The composition according to claim 3 wherein said two water soluble zinc salts are zinc acetate and zinc chloride. 18. The composition according to claim 3 wherein said two water soluble zinc salts are zinc acetate and zinc gluconate. 19. The method according to claim 11 wherein said two water soluble zinc salts are zinc acetate and zinc chloride. 20. The composition according to claim 11 wherein said two water soluble zinc salts are zinc acetate and zinc gluconate.

Details for Patent 9,034,391

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978	⤷ Try a Trial	2026-01-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2026-01-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2026-01-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2026-01-27
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	06/01/1989	⤷ Try a Trial	2026-01-27
Amgen, Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		⤷ Try a Trial	2026-01-27
Amgen, Inc.	PROCRIT	epoetin alfa	Injection	103234		⤷ Try a Trial	2026-01-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.